Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Clinical updates for metastatic hormone sensitive prostate cancer at ASCO 2019

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.19
Views: 3456

Prof Rob Jones, Prof Nick James, Prof Ian Davis, Prof Axel Merseburger

Professor Rob Jones introduces a session on the latest updates in the management of metastatic hormone sensitive prostate cancer (mHSPC) at ASCO 2019. He is joined by Professor Nick James, Professor Ian Davis and Professor Axel Merseburger.

Professor James provides an update on the STAMPEDE trial, Professor Merseburger provides an overview of the results of the TITAN trial and Professor Davis summarises the ENZAMET study presented at ASCO 2019. The experts discuss the distinguishing features of these studies and address the topic of sequential versus concurrent therapy for this patient group, debating whether data at ASCO has provided any evidence to support either therapeutic option.

The panel go on to discuss whether volume of disease impacts treatment response in patients with mHSPC and conclude the session by emphasising the importance of patient choice when selecting treatment for patients in this setting.

Summary of the STAMPEDE trial
Results from the TITAN trial
Key findings of the ENZAMET trial
Sequential versus combination therapy
Making the choice between docetaxel or androgen-receptor targeted therapy
Volume of disease and its effect on treatment choice

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation